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Abstract
Background: Tuberculosis (TB) remains a major world health problem. Around 2 billions of
people are infected by Mycobacterium tuberculosis, the causal agent of this disease. This fact accounts
for a third of the total world population and it is expected that 9 million people will become
infected each year. Only approximately 10% of the infected people will develop disease. However,
health care workers (HCW) are continually exposed to the bacilli at endemic sites presenting
increased chance of becoming sick. The objective of this work was to identify LTBI (latent
tuberculosis infection) among all asymptomatic HCW of a Brazilian Central Hospital, in a three year
follow up, and evaluate the humoral response among HCW with previous and recent LTBI to
recombinant HspX and GlcB from M. tuberculosis.
Methods: Four hundred and thirty seven HCW were screened and classified into three different
groups according to tuberculin skin test (TST) status: uninfected, previous LTBI and recent LTBI.
ELISA test were performed to determine the humoral immune response to HspX and GlcB.
Results: The levels of IgG and IgM against the HspX and GlcB antigens were the same among
HCW with recent and previous LTBI, as well as among non infected HCW. However, the IgM
levels to HspX was significantly higher among HCW with recent LTBI (OD = 1.52 ± 0.40) than
among the uninfected (OD = 1.09 ± 0.50) or subjects with previous LTBI (OD = 0.96 ± 0.51) (p <
0.001).
Conclusion: IgG and IgM humoral responses to GlcB antigens were similar amongst all studied
groups; nevertheless IgM levels against HspX were higher among the recent LTBI/HCW.
Background
Tuberculosis (TB) remains one of the world's major pub-
lic health problems. The World Health Organization
(WHO) estimated 8.9 million of new cases of TB in 2004
and that one third of the world's population is infected by
Mycobacterium tuberculosis (M. tb) [1,2]. Although the
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identification and cure of active, infectious cases of pul-
monary TB is the most cost-effective public health meas-
ure for the control of the disease, the detection and
treatment of individuals with latent TB infection (LTBI)
may also provide an important role in the fight against the
TB epidemic [2]. Different studies have demonstrated that
among subjects with recent LTBI, the risk for developing
active TB in the first year of follow up was 8 times higher
than in the subsequent seven years and that 82% of TB
cases developed active disease within 2 years of infection
[3,4]. The most common test used to determine if a per-
son has been infected by M. tb is the tuberculin skin test
(TST). Although of low cost and relatively simple to
administer, the TST suffers from a number of well-docu-
mented performance and logistical problems, such as the
need for individuals to return for test reading, the variabil-
ity and subjectivity in test application and reading and
low specificity [5,6].
In 2005, the FDA approved an IFN-γ assay for the diagno-
sis of LTBI. In this test, an enzyme-linked immunosorbent
assay (ELISA) detects the IFN-γ in fresh blood of sensitized
individuals when incubated with a specific antigen [7-9].
A meta-analysis of 75 studies evaluating the IFN-γ assay
for LTBI diagnosis suggests that the use of RD1 ESAT-6
and CFP-10 antigens can provide identification of LTBI in
individuals with high risk of active disease [8]. Further-
more, less cross-reaction with BCG vaccine and other
mycobacteria and the superior test management is in con-
trast to the variability of administration and interpreta-
tion of the TST. Even though the IFN-γ assay presents
higher specificity than the TST, this improved specificity is
observed only in low-TB-incidence settings. More over,
both tests (TST and IFN-γ assay) are not capable of distin-
guishing recent from previous (presumable old) latent M.
tuberculosis infection.
Immunological methods are attractive as screening or as
diagnostic tests for TB disease or infection because they
could be relatively rapid and simple. Challenges for devel-
opment of an effective immunological test include avoid-
ing cross-reactivity with BCG or mycobacteria other than
M. tb; consistent performance in genetically and immuno-
logically diverse populations; and the need to discrimi-
nate active TB from LTBI, as well as recent LTBI from
previous (old) LTBI. Serological ELISA tests can be candi-
dates for the screening of individuals at higher risk to
develop active TB, because they are rapid, usually present
a higher sensitivity and could be performed at lower
income countries due to their low cost. A significant
number of M. tb proteins induce specific humoral and cel-
lular immune responses and these antigens have been
shown to correlate with proven human M. tb infection or
disease [10-14]. Recent findings suggest that antigens like
16-kDa (HspX, Rv2031c) and 80-kDa antigen (GlcB,
Rv1837c) could have a specific response in individuals
with high risk of M. tb infection with recent LTBI [12-14].
Brazil presents one of the highest TB incidences in Latin
America (60/100,000) and is among the 22 countries with
the highest TB prevalence. Goiania, central Brazil, a mid
Brazilian city with one million people, presented in 2001
an incidence rate of 22/100,000. Although Goiania had a
reduced incidence rate when compared to the rest of the
country, the State Reference Hospital for Infectious dis-
ease (HDT) was the only hospital admitting TB cases from
the Central region of Brazil, which received a total of 350
TB patients in 2001, where 77% of them were smear pos-
itive [15,16]. Because of that, health care workers (HCW)
caring TB patients at HDT could be at higher risk to
become infected with TB and consequently with a supe-
rior chance to develop active TB.
The purpose of the present study was to evaluate the spe-
cific humoral response to HspX and GlcB among HCW
with previous and recent latent infection by M. tb.
Methods
Subject enrollment
The study setting was the TB State Reference center for
infectious disease: Hospital de Doenças Tropicais (HDT).
At the occasion of the enrollment, June 2001, a cross-sec-
tional study was conducted to determine the prevalence of
LTBI among all asymptomatic HCW of HDT age 18 years
and older without known history of active TB. After the
screening, HCW with no LTBI were prospectively enrolled
in a cohort study and were followed through 2002, 2003
and 2004 to determine the incidence LTBI within one
year. The complete study was approved by the Ethics
Committee of HDT and an informed written consent was
obtained from all study participants.
Clinical evaluation
During the cross-sectional evaluation, the medical history
of all HCW was obtained, including information on BCG
vaccination (during childhood or re-vaccination) and past
TB diagnosis or treatment. A physical examination was per-
formed. All HCW underwent a two-step TST applied to the
forearm using the Mantoux technique and read by a trained
and certificated professional (degree of intra-reader reliabil-
ity > 95% and inter-reader reliability ≥ 80%). All testing was
performed using purified protein derivative (PPD), RT23
(0.1 ml = 2 TU) (Staten Serum Institute, Copenhagen, Den-
mark). The first TST was read 48–72 h after application.
HCWs with a reading on the first TST of ≤ 9 mm induration
were classified as negative and the subject was invited to
return for a second TST applied 2 weeks after the first TST.
Boosting reaction was defined as having a reaction of ≥ 10
mm on the second TST with an increase in induration of at
least 6 mm compared to first TST [3,4]. Presence of an indu-BMC Infectious Diseases 2007, 7:148 http://www.biomedcentral.com/1471-2334/7/148
Page 3 of 9
(page number not for citation purposes)
ration of ≥ 10 mm in the first TST or a boosting in the sec-
ond TST defined the HCW as a case of previous LTBI.
Subjects with a negative result in the first TST and no boost-
ing in the second were considered not infected by M. tb
(uninfected HCWs) and were enrolled in the prospective
cohort. All enrolled participants of the cross-sectional eval-
uation and of the prospective cohort had a sample of
venous blood drawn and placed into glass tubes without
preservative or anticoagulant for serum separation and into
EDTA-coated tubes for whole blood and plasma separa-
tion. Fasting venous blood samples (5 ml) were collected
from each subject at the time of enrollment, stored at -
20°C, and thawed only once at the time of the serology
assays. All samples were tested for human immunodefi-
ciency virus infection.
All HCWs enrolled in the prospective cohort were evalu-
ated annually. During the annual evaluation a medical
history, physical examination and a new TST were per-
formed. HCW presenting or referring to respiratory symp-
toms ≥ 2 weeks underwent a chest radiograph and had
two sputum samples (spontaneous or induced) collected
and stained with Ziehl-Neelsen and cultured on Löwen-
stein-Jensen media. We considered patients with a posi-
tive culture for M. tb from a respiratory sample as
pulmonary TB case. A 10 mm increase in the size of the
induration compared to the TST from the previous year
was defined as a conversion. For the purpose of this study
a HCW with a TST conversion within one year was classi-
fied as a recent LTBI case. HCW with no conversion docu-
mented and a TST induration ≤ 10 mm were invited to
return for a new evaluation and TST annually for the fol-
lowing 3 years (2002, 2003 and 2004). HCW with recent
LBTI underwent isoniazid prophylaxis treatment during
six months (300 mg/day). HCW that presented TB symp-
toms and had a sputum stained positive by the Ziehl
Neelsen method were treated according to the Brazilian
standard regimen I, which is composed of rifampin (600
mg/day), isoniazid (300 mg/day) and pyrazinamide (400
mg/day) [17].
Excluded from the study during the cross-sectional evalu-
ation were HCWs who had a second TST ≥ 10 mm but
who did not meet criteria for booster phenomenon (an
increase in induration < 6 mm related to first TST). HCWs
enrolled in the cohort who had no conversion docu-
mented but TST induration ≥ 10 mm, those with positive
HIV test and those who missed the yearly evaluation or
did not come for TST reading were also excluded of the
study.
Laboratory evaluation
Antigen preparation: Purified recombinant antigen pro-
teins HspX and GlcB from M. tuberculosis were obtained
from the Colorado State University TB Research (con-
tract number: NIH, NO1-AI-75320). CSU protocols
provide purified recombinant protein, free of other E.
coli protein and LPS contaminations [18].
Serology testing was performed using an in house
ELISA technique. Ninety-six-well microtiter plates
(NUNC-immunoplate) were coated with 50 μl of
recombinant HspX and or GlcB antigens from M. tuber-
culosis, 2.5 μg/ml in 0.015 M carbonate buffer, pH 9.6
(PA, Vetec). Plates were coated overnight at 4°C. After
this incubation period, the plates were blocked with 1%
skim milk (Nestle, 100 μl/well) in buffered carbonate-
bicarbonate pH 9.6 and incubated for another 2 hours
at 37°C. After washing 5 times with PBS 0.05% Tween
20 (PA, Merck), sera samples were diluted to 1/100 in
PBS and were added in duplicate to the wells and incu-
bated for 2 hours. Next, after an exhaustive washing
was performed, 50 μl ml of conjugate solution (peroxi-
dase-labeled anti-human IgM (1/15000, IgM-HRP,
ZYMED LaboratoriesR) or peroxidase-labeled anti-
human IgG conjugate (1/5000, IgG-HRP, BIO-RADR),
was added into each well. Then the plate was incubated
for one hour at 37°C, and after washing, 50 μl/well of
substrate solution (citrate-phosphate buffer pH 5.1
(PA, Labsynth), OPD (1 μg/ml, Sigma, USA) and
hydrogen peroxide 30 vol (PA, Vetec)) were added.
Finally, after 15 min in the dark, 50 μl/well of stop
solution (sulfuric acid 4 N (PA, Vetec)) was pipetted
into each well and the optical density (OD) was meas-
ured at 492 nm in ELISA microplate reader (Thermo
Labsystem-Multiskan, Flow Laboratories, McLean, Va).
Immunoenzymatic assays were performed blindly by a
lab technician, and were developed and standardized in
our laboratory for the measurement of antibodies (IgM
and IgG) against HspX and GlcB antigens. Each test was
performed in duplicate, and the mean absorbance of
the wells with no antigen was subtracted from those of
the wells with the proteins antigens prior to analysis
[19]. In order to exclude cross reactivity due to E. coli
contamination or to the skim milk, the sera were pre
absorbed with E. coli lysate (Promega) or with skim
milk for one hour at 37°C and then analyzed in our in
house ELISA technique. There were no cross reactivity
affecting the ELISA results (data not shown).
Statistical analysis
Student's t-test was performed to compare the means of
continuous variables and Chi-square (or Fisher test when
applicable) was used for dichotomous variables. One-way
ANOVA was performed to compare the variance of optical
density (OD) from different groups. Differences were con-
sidered significant at a P < 0.05. The analysis was per-
formed using SPSS Version 11.0.BMC Infectious Diseases 2007, 7:148 http://www.biomedcentral.com/1471-2334/7/148
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Results
Four hundred thirty seven HCW were initially evaluated.
A flowchart of screened and followed HCW from June
2001 through June 2004 is presented in Figure 1.
The exclusion rate for reasons described above was 13.5%
(59/437).
Flow of health care workers evaluated and prospectively enrolled in the study Figure 1
Flow of health care workers evaluated and prospectively enrolled in the study. TST = Tuberculin Skin Test;  LTBI = latent 
tuberculosis infection;  HCW = health care workers.
HCWs evaluated in June 2001
N= 437
First TST
TST ≥ 10 mm (LTBI)
N=180
TST ≤ 9m m
N= 257
Second TST (2 weeks later)
Booster positive (LTBI)
N=31
Uninfected HCW (prospectively enrolled)
N=159
Lost
N=67
2002 2003 2004
HCW tested 131 90 40
TST positive
“conversion”
28
(21.3%)
12
(13.3%)
3
(7.5%)BMC Infectious Diseases 2007, 7:148 http://www.biomedcentral.com/1471-2334/7/148
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A total of 211 HCW were identified as infected by M. tb
during the cross-sectional evaluation and were classified
as a case of previous LTBI. Sixty seven HCW were excluded
because they refused to participate or did not return for
the second TST two weeks after the first one. One hundred
fifty nine HCW were classified as uninfected and were pro-
spectively enrolled in the study. During the three years of
follow up a total of 27% (43/159) of the HCW converted
their TST and were classified as a recent LTBI according the
study definition. Eighteen percent (28/159) of HCW were
lost to follow-up in 2002, 13% (13/103) in 2003 and
49% (38/78) in 2004. The yearly rate of TST conversion
was 21.3% (28/131), 13.3% (12/90) and 7.5% (3/40) in
2002, 2003 and 2004, respectively. The demographic data
of all HCW is presented in Table 1. Around 80% of all
HCW analyzed were female, with an average age of 40.9 ±
10.2 years. Although the BCG vaccination status varied
among the groups, the statistical analysis showed that the
HCW groups were equally distributed (P = 0.505).
Table 2 presents the response of IgM and IgG to the
recombinant antigens in each group evaluated. The
humoral response of IgM to HspX was statistically higher
among individuals with recent LTBI than among the unin-
fected (P < 0.0001) as well as among individuals with pre-
vious LTBI (P < 0.0001). There was no difference in the
humoral response of IgG to HspX and of IgM and IgG to
GlcB among all three groups. Figure 2 shows a dot plot
distribution of the humoral response to different antigens
among previous LTBI, recent LTBI and uninfected HCW.
In order to verify if the BCG vaccination had any effect on
the IgM response to these antigens, the response to HspX
and GlcB stratified according to their BCG vaccination sta-
tus among the HCW groups was analyzed. There was no
difference between IgM humoral response to HspX (P =
0.462) or GlcB (P = 0.607) (Table 3 and data not shown).
The same inquiry was done regarding IgG responses and
no difference was observed (data not shown). HCW that
recently converted their TST (rLTBI) also presented IgM
levels that did not suffer BCG statuses influence (P  =
0,567). In addition, the time after BCG vaccination
among HCW did not interfere with the humoral
responses (P = 0,608).
The sera from rLBTI individuals were analyzed before and
after TST conversion. To verify if the TST recent conversion
reflected on the IgM response against HspX, a kinetic of
the response of the 43 HCW was analyzed and is pre-
sented on Figure 3. As expected the IgM levels against
HspX increased after TST conversion (P < 0.001).
Discussion
Our study was done in Goiania, a city with one of the best
Brazilian quality of life, which receives infectious disease
patients from center and mid west region at its State
Table 1: Demographic data and vaccination status of 413 HCWs evaluated at least once during the period of the study.
Uninfected (n = 159) Previous LTBI (n = 211) Recent LTBI (n = 43)
Female/male 137/22 171/40 37/6
Age – range 18–62 18–68 18–62
mean (SD) 39.78 (± 10.3) 41.82 (± 10.2) 39.91 (± 10.8)
Previous BCG 100 (62.9%) 163 (77.3%) 30 (59.8%)
old application 92 (92%) 149 (91.4%) 29 (96.6%)
recent application* 8 (8%) 14 (8.6%) 1 (3.4%)
SD = standard deviation; BCG = Bacilli Calmette-Guérin; LTBI = latent tuberculosis infection;
*Vaccination in the last five years
Table 2: ELISA optical densities with HspX and GlcB recombinant antigens obtained for the different groups investigated.
HspX GlcB
IgG m ± sd IgM m ± sd IgG m ± sd IgM m ± sd
Uninfected 0.231 ± 0.110 1.090 ± 0.504 0.975 ± 0.614 0.947 ± 0.263
Previous LTBI 0.223 ± 0.121 0.957 ± 0.510 0.977 ± 0.595 0.942 ± 0.314
Recent LTBI 0.252 ± 0.167 1.519 ± 0.394* 0.816 ± 0.574 1.053 ± 0.338
LTBI = latent tuberculosis infection; m = mean of optical density; sd = standard deviation
*IgM against HspX specific humoral responses is significantly higher for recent LTBI than for uninfected (P < 0.0001), and LTBI (P < 0.0001) 
individuals. There was no statistical difference between IgG OD against HspX among the different groups. There was no statistical difference 
between IgG and IgM OD against GlcB.BMC Infectious Diseases 2007, 7:148 http://www.biomedcentral.com/1471-2334/7/148
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Table 3: Optical density of IgM ELISA against HspX obtained for the different groups according to their vaccination status.
IgM HspX
BCG (-) m ± sd old BCG m ± sd recent BCGb m ± sd
Uninfected 1.154 ± 0.481 1.108 ± 0.511 0.927 ± 0.535
LTBI 1.035 ± 0.622 0.986 ± 0.445 0.991 ± 0.744
r LTBI 1,580 ± 0.505 1,328 ± 0.477 1,560a
LTBI = latent tuberculosis infection; m = mean of optical density; sd = standard deviation
a Only one HCW had recent BCG vaccination (last five years).
b Vaccination in the last five years. There was no influence of BCG vaccination to the IgM responses for HspX.
Serologic response of study subjects by indirect ELISA to the recombinant antigens Figure 2
Serologic response of study subjects by indirect ELISA to the recombinant antigens. A. Levels of HspX IgM and IgG antibodies 
in serum from HCW uninfected (n = 159), LTBI (n = 211) and recent LTBI (n = 43). B. Levels of GlcB IgM and IgG antibodies 
in serum from HCW uninfected, LTBI and recent LTBI. Horizontal bars represent the mean antibody levels in the groups. IgM 
levels in recent LTBI were significantly higher than in those uninfected and LTBI (P < 0.0001).
IgG ELISA-HspX
Uninfected LTBI recent LTBI
0
1
2
3
Clinical Status
O
D
IgM ELISA-HspX
Uninfected LTBI recent LTBI
0
1
2
3 p<0,0001
p<0,0001
Clinical Status
O
D
IgG ELISA-GlcB
Uninfected LTBI recent LTBI
0
1
2
3
Clinical Status
O
D
IgM ELISA-GlcB
Uninfected LTBI recent LTBI
0
1
2
3
Clinical Status
O
D
A
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Reference Center for infectious disease: Hospital de
Doenças Tropicais (HDT). All hospital workers were
invited to participate, 437 out of 540 HDT HCW were
enrolled. Although, Goiania's TB incidence was 22/
100,000 persons, a low rate for a Brazilian city, an exces-
sively high positive TST rates were observed among the
HCW. Two hundred and eleven HCW (48%) were TST
positive at the enrollment time and were classified as pre-
senting latent TB infection. This fact could be justified
because HDT admitted a median range of ~350 TB cases/
year during the five years before the experiment setting,
where most of them were smear positive, and also for the
reason that the hospital rooms did not present HEPA fil-
ters and the HCW did not use protective garments until
the time of the study. Similar results were obtained in
other Brazilian Hospital [20]. After the cross-sectional
study, the HCW were instructed to follow standard opera-
tion procedures to avoid the contamination which culmi-
nated with a lower TST conversion rates on the yearly
follow up. Also in 2003, HEPA filters were installed at the
hospital rooms in order to receive TB patients [15,16].
Our findings show that the OD range of IgG and IgM
against the HspX and GlcB antigens was the same among
HCW with recent and previous LTBI, as well as among
non infected HCW (Table 2). Also, Figure 2A clearly
shows that the O.D. values of HCW with recent LTBI were
in the range detected among subjects with previous LTBI
and even in the uninfected group. On the basis of these
findings the definition of a cut-off value discriminating
recent TBLI from previous or uninfected HCW would not
be feasible. This result is similar to the findings of Davi-
dow et al (2005) that evaluated the IgG humoral response
to six M. tb antigens (including HspX) in 53 individuals
with active TB, 218 with inactive TB, 32 with LTBI and 50
uninfected subjects (asymptomatic subjects with negative
TST). They showed that the uninfected subjects and indi-
viduals with LTBI were serologically indistinguishable
[14]. Also, a study using sera in a setting with a high prev-
alence of TB showed the same conclusion in regards to the
humoral response of IgG to the same antigen (HspX or α-
crystallin) among active TB patients and TB contacts with-
out TST results [10].
The mean IgM OD level for HspX among HCW with
recent LTBI (OD = 1,519) was significantly higher (p <
0,001) than among HCW previously infected (OD =
0.957) and not infected (OD = 1.090), suggesting a possi-
ble role of this antigen in identifying recent TB infection.
To emphasize this hypothesis, the kinetic of the response
by recent LTBI individuals showed an increase in IgM lev-
els against HspX as a consequence of the TST conversion
(Fig. 3). A study evaluating the immune cellular response
to the antigen HspX reported an association between the
interferon gamma production to antigen HspX and TB
latency [13]. Another study demonstrated that the cellular
immune response and the humoral IgM production start
earlier than the ability of the host to produce IgG against
this antigen. Thus, different stages of TB may be character-
ized by a particular antibody or cellular immune response
profile against several antigens. Conde et al (2004)
reported different responses using IgA and IgG to Myco-
bacterial P-90 antigen for the diagnosis of active pulmo-
nary TB. They also showed a relatively high IgA humoral
response among healthy close contacts when 54% of
active pulmonary TB patients presented positive results
compared with a low response among healthy controls
when only 8% presented a positive ELISA result [21]. In
addition, the clinical state of the disease can affect the spe-
cific humoral response. Kasermann et al (2005), analyz-
ing pleural fluid of TB patients with pleurisy,
demonstrated the presence of specific IgA against MPT-64
and MT-10.3 in the pleural fluid and the authors sug-
gested that this test can be used for the diagnosis of pleural
TB [22].
Even though different humoral responses to M. tb anti-
gens at different stages of active TB disease have already
been well demonstrated, to our knowledge, this is the first
report of a specific humoral response to HspX in recent
latent M. tb infection. Our findings expand the concept
that HspX (the 16 kDa antigen, sometimes called 14 kDa)
could distinguish recent LTBI from previous LTBI
although the range of the optical density was high in both
groups. Prior active TB disease or infection with mycobac-
teria other than M. tb might contribute to a low specificity
of serological antibody based tests for TB.
Our findings show no significant humoral response (IgM
and IgG) to GlcB among the different stages of M. tb infec-
tion. Singh et al (2005) and Achkar et al (2006) used indi-
rect ELISA to show the presence of GlcB associated with
MPT-51 specific antibodies in ~90% of HIV seropositive
individuals who developed active TB disease and an
absence of response among individuals with LTBI and
uninfected subjects. These authors suggested that these
specific antibody detections could serve as markers to
identify incipient infection with M. tb. [23,24]. However,
these reports used a combination ELISA measuring spe-
cific IgG and IgA to these antigens. Furthermore, there was
no discrimination between TST positive and TST negative
individuals; in that case the LTBI subjects were not well
classified. In our study, we evaluated isolated IgM and IgG
humoral immune response to HspX and GlcB.
It has already been reported that the vaccination with M.
bovis bacillus Calmette-Guerin (BCG) may contribute to a
low specificity of serological tests for TB [25,26]. Mori et
al (2004) examined a whole blood IFN-γ test using ESAT6
and CFP10 in 216 healthy BCG-vaccinated JapaneseBMC Infectious Diseases 2007, 7:148 http://www.biomedcentral.com/1471-2334/7/148
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adults and 118 patients with TB [27]. The results demon-
strated that this test was highly specific (98%) and sensi-
tive (89%) for M. tb infection and was unaffected by BCG
vaccination [27]. Although it has been shown elsewhere
that HspX accumulates in long-term stationary-phase cul-
tures of M. bovis- BCG [28], our findings suggest no inter-
ference of BCG vaccination in the IgM humoral response
to HspX. Using the knowledge that BCG affects the TST
conversion during five years after the vaccination [3,4],
the results of the groups studied here were compared
based on the time of their BCG vaccination (Table 3).
HCW with recent BCG vaccination (less than five years) of
uninfected, LTBI and rLTBI individuals did not changed
the humoral response to the recombinant antigens HspX
and GlcB.
The present study has several limitations. The serologic
tests were performed retrospectively, using serum that had
been stored. Although no serum had been thawed more
than once, we cannot formally exclude the possibility that
serum storage conditions adversely affected the test per-
formance, although we believe that this is unlikely. The
cross reactivity to E. coli proteins or to the skim milk were
excluded during the standardization. The definition used
in the study for recent LTBI might not be appropriate as it
is not possible to distinguish through a yearly TST if the
M. tb infection occurred 2 weeks or 12 months prior to the
test. New studies evaluating the response to HspX among
TST conversion documented within 12 weeks after a neg-
ative TST (such as during the evaluation of close contacts
of an active pulmonary TB case) instead of 12 months
could help us to better understand the role of this antigen
in recent LTBI.
Conclusion
We conclude that the OD range of IgG and IgM against
antigens HspX and GlcB was the same among subjects
with recent and previous LTBI, as well as among non
infected individuals. However, the OD mean of IgM
response to HspX was significantly different among the
different stages of M. tb infection. This finding suggests a
possible use of HspX as a marker for recent LTBI, even in
a BCG vaccinated population, perhaps using different
techniques to evaluate the antigen response. New studies
are necessary to evaluate this hypothesis.
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